COVID-19 vaccines

Pfizer CEO sees annual COVID-19 vaccine rather than frequent boosters

Reuters
Pfizer CEO sees annual COVID-19 vaccine rather than frequent boosters

PFIZER VACCINE. Vials labeled "Vaccine Coronavirus COVID-19" and a syringe are seen in front of a displayed Pfizer logo in this illustration taken December 11, 2021.

Dado Ruvic/Reuters

Pfizer Inc CEO Albert Boula says they could be ready to file for approval for a redesigned vaccine to fight the Omicron variant as soon as March

JERUSALEM – Pfizer Inc. Chief Executive Albert Bourla said on Saturday, January 22, that an annual coronavirus vaccine would be preferable to more frequent booster shots in fighting the COVID-19 pandemic.

Pfizer/BioNtech’s COVID-19 vaccine has shown to be effective against severe disease and death caused by the heavily-mutated Omicron variant but less effective in preventing transmission.

With cases soaring, some countries have expanded COVID-19 vaccine booster programs or shortened the gap between shots as governments scramble to shore up protection.

In an interview with Israel’s N12 News, Bourla was asked whether he sees booster shots being administered every four to five months on a regular basis.

“This will not be a good scenario. What I’m hoping [is] that we will have a vaccine that you will have to do once a year,” Bourla said.

“Once a year – it is easier to convince people to do it. It is easier for people to remember,” Boula said. “So from a public health perspective, it is an ideal situation. We are looking to see if we can create a vaccine that covers Omicron and doesn’t forget the other variants and that could be a solution.”

Pfizer CEO sees annual COVID-19 vaccine rather than frequent boosters

Bourla has said Pfizer could be ready to file for approval for a redesigned vaccine to fight Omicron, and mass produce it, as soon as March.

Citing three studies, the United States Centers for Disease Control and Prevention (CDC) said on Friday, January 21, that a third dose of an mRNA vaccine is key to fighting Omicron, providing 90% protection against hospitalization.

A preliminary study published by Israel’s Sheba Medical Center on Monday, January 17, found that a fourth shot increases antibodies to even higher levels than the third but was likely not enough to fend off Omicron. Nonetheless, a second booster was still advised for risk groups, Sheba said. – Rappler.com